The FDA has approved icotrokinra, an oral interleukin-23 receptor antagonist, for patients aged 12 years and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or...
A multinational cross-sectional survey of children and adolescents with moderate-to-severe atopic dermatitis found substantial disease burden, with distinct physical and psychosocial impacts by age group.
...
In a randomized clinical trial, investigators evaluated whether hydrocolloid dressings offer improved scar appearance and healing convenience compared to daily petroleum ointment after dermatologic...
A new longitudinal study published in the Journal of the American Academy of Dermatology evaluated more than a decade of data from adults living with HIV, revealing a steady decline in dermatologic disease...
Two-year data from the long-term phase 3 ALLEGRO-LT study suggest ritlecitinib maintains long-term clinical efficacy with a manageable safety profile in patients with moderate to severe alopecia areata.
...
New findings from a large, pragmatic trial found that daily full-body emollient application beginning by 9 weeks of age significantly reduced the cumulative incidence of atopic dermatitis by 24 months.
...
A randomized clinical trial found that adding wrist-ankle acupuncture to standard pharmacological treatment significantly improved pain relief in patients with acute herpes zoster.
With three FDA-approved treatments now available, clinicians must learn to spot the early signs and understand the evolving science behind hidradenitis suppurativa (HS), a painful and stigmatizing disease....
In their secondary analysis of the Surgery Versus Combined Treatment With Curettage and Imiquimod for Nodular Basal Cell Carcinoma randomized clinical trial, researchers evaluated the 5-year efficacy of...
